Aqueous humor erythropoietin levels in open-angle glaucoma patients with and without TTR V30M familial amyloid polyneuropathy

Molecular Vision

Volumn 20, Issue , 2014, Pages 970-976

  Beirão, João M ^a,b   Moreira, Luciana M ^b,c   Oliveira, João C ^a   Menéres, Maria J ^a,b   Pessoa, Bernardete B ^a   Matos, Maria E ^b   Costa, Paulo P ^b,c   Torres, Paulo A ^a,b   Beirão, Idalina B ^a,b  

^a HOSPITAL DE SANTO ANTÓNIO   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c NATIONAL INSTITUTE OF HEALTH   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN;

ADULT; AQUEOUS HUMOR; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FAMILIAL AMYLOID POLYNEUROPATHY; FEMALE; GLAUCOMA SURGERY; HUMAN; INTRAOCULAR PRESSURE; INTRAOCULAR PRESSURE ABNORMALITY; LIVER TRANSPLANTATION; MALE; NEUROPROTECTION; OPEN ANGLE GLAUCOMA; PHACOEMULSIFICATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN SYNTHESIS; TREATMENT INDICATION; VITRECTOMY;

AMYLOID NEUROPATHIES, FAMILIAL; AQUEOUS HUMOR; DEMOGRAPHY; ERYTHROPOIETIN; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; MUTANT PROTEINS;

EID: 84903885179     PISSN: None     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (71)

1. Agar A, Yip SS, Hill MA, Coroneo MT. Pressure related apoptosis in neuronal cell lines. J Neurosci Res 2000; 60: 495-503. [PMID: 10797552].
2. Flammer J, Orgül S. Optic nerve blood-flow abnormalities in glaucoma. Prog Retin Eye Res 1998; 17: 267-89. [PMID: 9695795].
3. Cioffi GA. Ischemic model of optic nerve injury. Trans Am Ophthalmol Soc 2005; 103: 592-613. [PMID: 17057819].
4. Tezel G, Wax MB. Hypoxia-inducible factor 1alpha in the glaucomatous retina and optic nerve head. Arch Ophthalmol 2004; 122: 1348-56. [PMID: 15364715].
5. Evans DW, Hosking SL, Gherghel D, Bartlett JD. Contrast sensitivity improves after brimonidine therapy in primary open angle glaucoma: a case for neuroprotection. Br J Ophthalmol 2003; 87: 1463-5. [PMID: 14660453].
6. Gordon MO, Beiser JA, Brandt JD, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish RK 2nd, Wilson MR, Kass MA. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol 2002; 120: 714-20. [PMID: 12049575].
7. Izzotti A, Bagnis A, Saccà SC. The role of oxidative stress in glaucoma. Mutat Res 2006; 612: 105-14. [PMID: 16413223].
8. Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E. Early Manifest Glaucoma Trial Group. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol 2003; 121: 48-56. [PMID: 12523884].
9. Saraiva MJ, Costa PP, Goodman DS. Studies on plasma transthyretin (prealbumin) in familial amyloidotic polyneuropathy, Portuguese type. J Lab Clin Med 1983; 102: 590-603. [PMID: 6311926].
10. Saraiva MJ, Costa PP, Birken S, Goodman DS. Presence of an abnormal transthyretin (prealbumin) in Portuguese patients with familial amyloidotic polyneuropathy. Trans Assoc Am Physicians 1983; 96: 261-70. [PMID: 6208668].
11. Saraiva MJ, Birken S, Costa PP, Goodman DS. Amyloid fibril protein in familial amyloidotic polyneuropathy, Portuguese type. Definition of molecular abnormality in transthyretin (prealbumin). J Clin Invest 1984; 74: 104-19. [PMID: 6736244].
12. Ando Y, Araki S, Ando M. Transthyretin and familial amyloidotic polyneuropathy. Intern Med 1993; 32: 920-2. [PMID: 8204970].
13. Ando E, Ando Y, Okamura R, Uchino M, Ando M, Negi A. Ocular manifestations of familial amyloidotic polyneuropathy type I: long-term follow up. Br J Ophthalmol 1997; 81: 295-8. [PMID: 9215058].
14. Sandgren O, Kjellgren D, Suhr OB. Ocular manifestations in liver transplant recipients with familial amyloid polyneuropathy. Acta Ophthalmol (Copenh) 2008; 86: 520-4. [PMID: 18435819].
15. Beirão M, Matos E, Beirão I, Costa PP, Torres P. Anticipation of presbyopia in Portuguese familial amyloidosis ATTR V30M. Amyloid 2011; 18: 92-7. [PMID: 21591979].
16. Kimura A, Ando E, Fukushima M, Koga T, Hirata A, Arimura K, Ando Y, Negi A, Tanihara H. Secondary glaucoma in patients with familial amyloidotic polyneuropathy. Arch Ophthalmol 2003; 121: 351-6. [PMID: 12617705].
17. Jelkmann W. Erythropoietin: structure, control of production, and function. Physiol Rev 1992; 72: 449-89. [PMID: 1557429].
18. Ghezzi P, Brines M. Erythropoietin as an antiapoptotic, tissue-protective cytokine. Cell Death Differ 2004; 11: Suppl 1S37-44. [PMID: 15243580].
19. Becerra SP, Amaral J. Erythropoietin-an endogenous retinal survival factor. N Engl J Med 2002; 347: 1968-70. [PMID: 12477950].
20. Dreixler JC, Hagevik S, Hemmert JW, Shaikh AR, Rosenbaum DM, Roth S. Involvement of erythropoietin in retinal ischemic preconditioning. Anesthesiology 2009; 110: 774-80. [PMID: 19322943].
21. Inomata Y, Hirata A, Takahashi E, Kawaji T, Fukushima M, Tanihara H. Elevated erythropoietin in vitreous with ischemic retinal diseases. Neuroreport 2004; 15: 877-9. [PMID: 15073535].
22. Sakanaka M, Wen TC, Matsuda S, Masuda S, Morishita E, Nagao M, Sasaki R. In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci USA 1998; 95: 4635-40. [PMID: 9539790].
23. Tsai JC, Song BJ, Wu L, Forbes M. Erythropoietin: a candidate neuroprotective agent in the treatment of glaucoma. J Glaucoma 2007; 16: 567-71. [PMID: 17873720].
24. Tsai JC, Wu L, Worgul B, Forbes M, Cao J. Intravitreal administration of erythropoietin and preservation of retinal ganglion cells in an experimental rat model of glaucoma. Curr Eye Res 2005; 30: 1025-31. [PMID: 16282136].
25. Villa P, Bigini P, Mennini T, Agnello D, Laragione T, Cagnotto A, Viviani B, Marinovich M, Cerami A, Coleman TR, Brines M, Ghezzi P. Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J Exp Med 2003; 198: 971-5. [PMID: 12975460].
26. Wang ZY, Shen LJ, Tu L, Hu DN, Liu GY, Zhou ZL, Lin Y, Chen LH, Qu J. Erythropoietin protects retinal pigment epithelial cells from oxidative damage. Free Radic Biol Med 2009; 46: 1032-41. [PMID: 19136057].
27. Hernández C, Fonollosa A, García-Ramírez M, Higuera M, Catalán R, Miralles A, García-Arumí J, Simó R. Erythropoietin is expressed in the human retina and it is highly elevated in the vitreous fluid of patients with diabetic macular edema. Diabetes Care 2006; 29: 2028-33. [PMID: 16936148].
28. Fu QL, Wu W, Wang H, Li X, Lee VW, So KF. Up-regulated endogenous erythropoietin/erythropoietin receptor system and exogenous erythropoietin rescue retinal ganglion cells after chronic ocular hypertension. Cell Mol Neurobiol 2008; 28: 317-29. [PMID: 17554621].
29. García-Ramírez M, Hernández C, Simó R. Expression of erythropoietin and its receptor in the human retina: a comparative study of diabetic and nondiabetic subjects. Diabetes Care 2008; 31: 1189-94. [PMID: 18332162].
30. Cumurcu T, Bulut Y, Demir HD, Yenisehirli G. Aqueous humor erythropoietin levels in patients with primary open-angle glaucoma. J Glaucoma 2007; 1: 645-8.
31. Wang ZY, Zhao KK, Zhao PQ. Erythropoietin is increased in aqueous humor of glaucomatous eyes. Curr Eye Res 2010; 35: 680-4. [PMID: 20673044].
32. Mokbel TH, Ghanem AA, Kishk H, Arafa LF, El-Baiomy AA. Erythropoietin and soluble CD44 levels in patients with primary open-angle glaucoma. Clin Experiment Ophthalmol 2010; 38: 560-5. [PMID: 20456444].
33. Dirnagl U, Simon RP, Hallenbeck JM. Ischemic tolerance and endogenous neuroprotection. Trends Neurosci 2003; 26: 248-54. [PMID: 12744841].
34. Wenger RH. Cellular adaptation to hypoxia: O2-sensing protein hydroxylases, hypoxia-inducible transcription factors, and O2-regulated gene expression. FASEB J 2002; 16: 1151-62. [PMID: 12153983].
35. Arjamaa O, Nikinmaa M. Oxygen-dependent diseases in the retina: role of hypoxia-inducible factors. Exp Eye Res 2006; 83: 473-83. [PMID: 16750526].
36. Silva M, Grillot D, Benito A, Richard C, Nuñez G, Fernández-Luna JL. Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through Bcl-XL and Bcl-2. Blood 1996; 88: 1576-82. [PMID: 8781412].
37. Sakanaka M, Wen TC, Matsuda S, Masuda S, Morishita E, Nagao M, Sasaki R. In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci USA 1998; 95: 4635-40. [PMID: 9539790].
38. Kawakami M, Sekiguchi M, Sato K, Kozaki S, Takahashi M. Erythropoietin receptor-mediated inhibition of exocytotic glutamate release confers neuroprotection during chemical ischemia. J Biol Chem 2001; 276: 39469-75. [PMID: 11504731].
39. Genc S, Koroglu TF, Genc K. Erythropoietin as a novel neuroprotectant. Restor Neurol Neurosci 2004; 22: 105-19. [PMID: 15272145].
40. Fisher JW. Erythropoietin: physiology and pharmacology update. Exp Biol Med (Maywood) 2003; 228: 1-14. [PMID: 12524467].
41. Grimm C, Wenzel A, Groszer M, Mayser H, Seeliger M, Samardzija M, Bauer C, Gassmann M, Remé CE. HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal degeneration. Nat Med 2002; 8: 718-24. [PMID: 12068288].
42. Katsura Y, Okano T, Matsuno K, Osako M, Kure M, Watanabe T, Iwaki Y, Noritake M, Kosano H, Nishigori H, Matsuoka T. Erythropoietin is highly elevated in vitreous fluid of patients with proliferative diabetic retinopathy. Diabetes Care 2005; 28: 2252-4. [PMID: 16123502].
43. Watanabe D, Suzuma K, Matsui S, Kurimoto M, Kiryu J, Kita M, Suzuma I, Ohashi H, Ojima T, Murakami T, Kobayashi T, Masuda S, Nagao M, Yoshimura N, Takagi H. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med 2005; 353: 782-92. [PMID: 16120858].
44. Beirão I, Lobato L, Costa PM, Fonseca I, Mendes P, Silva M, Bravo F, Cabrita A, Porto G. Kidney and anemia in familial amyloidosis type I. Kidney Int 2004; 66: 2004-9. [PMID: 15496172].
45. Bucciantini M, Calloni G, Chiti F, Formigli L, Nosi D, Dobson CM, Stefani M. Prefibrillar amyloid protein aggregates share common features of cytotoxicity. J Biol Chem 2004; 279: 31374-82. [PMID: 15133040].
46. Reixach N, Deechongkit S, Jiang X, Kelly JW, Buxbaum JN. Tissue damage in the amyloidoses: Transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture. Proc Natl Acad Sci USA 2004; 101: 2817-22. [PMID: 14981241].
47. Junk AK, Mammis A, Savitz SI, Singh M, Roth S, Malhotra S, Rosenbaum PS, Cerami A, Brines M, Rosenbaum DM. Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury. Proc Natl Acad Sci USA 2002; 99: 10659-64. [PMID: 12130665].
48. Nassiri N, Nassiri N, Majdi M, Mehrjardi HZ, Shakiba Y, Haghnegahdar M, Heidari AB, Djalilian AR, Mirahmadian M. Erythropoietin levels in aqueous humor of patients with glaucoma. Mol Vis 2012; 18: 1991-5. [PMID: 22876126].
49. Hamid M, Fahmy I, Moemen L, El-Beltagy T. Role of matrix metalloproteinase-2 and its inhibitor and erythropoietin in the pathogenesis of pseudoexfoliative glaucoma. Australian J Bas Appl Sci 2008; 2: 752-6.
50. Beirão I, Moreira L, Porto G, Lobato L, Fonseca I, Cabrita A, Costa PM. Low erythropoietin production in familial amyloidosis TTR V30M is not related with renal congophilic amyloid deposition. A clinicopathologic study of twelve cases. Nephron Clin Pract 2008; 109: c95-9. [PMID: 18596378].
51. Beirão I, Moreira L, Barandela T, Lobato L, Silva P, Gouveia CM, Carneiro F, Fonseca I, Porto G, Pinho E, Costa P. Erythropoietin production by distal nephron in normal and familial amyloidotic adult human kidneys. Clin Nephrol 2010; 74: 327-35. [PMID: 20979939].
52. Sousa MM, Cardoso I, Fernandes R, Guimarães A, Saraiva MJ. Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates. Am J Pathol 2001; 159: 1993-2000. [PMID: 11733349].
53. Fiszman ML, Di Egidio M, Ricart KC, Repetto MG, Borodinsky LN, Llesuy SF, Saizar RD, Trigo PL, Riedstra S, Costa PP, Villa AM, Katz N, Lendoire JC, Sica RE. Evidence of oxidative stress in familial amyloidotic polyneuropathy type 1. Arch Neurol 2003; 60: 593-7. [PMID: 12707074].
54. Sousa MM, Du Yan S, Fernandes R, Guimaraes A, Stern D, Saraiva MJ. Familial amyloid polyneuropathy: receptor for advanced glycation end products-dependent triggering of neuronal inflammatory and apoptotic pathways. J Neurosci 2001; 21: 7576-86. [PMID: 11567048].
55. Sousa MM, Yan SD, Stern D, Saraiva MJ. Interaction of the receptor for advanced glycation end products (RAGE) with transthyretin triggers nuclear transcription factor kB (NF-kB) activation. Lab Invest 2000; 80: 1101-10. [PMID: 10908156].
56. Monteiro FA, Sousa MM, Cardoso I, do Amaral JB, Guimarães A, Saraiva MJ. Activation of ERK1/2 MAP kinases in familial amyloidotic polyneuropathy. J Neurochem 2006; 97: 151-61. [PMID: 16515552].
57. Benson MD. Liver transplantation and transthyretin amyloidosis. Muscle Nerve 2013; 47: 157-62. [PMID: 23169427].
58. Jelkmann W. Proinflammatory cytokines lowering erythropoietin production. J Interferon Cytokine Res 1998; 18: 555-9. [PMID: 9726435].
59. Vannucchi AM, Grossi A, Rafanelli D, Statello M, Cinotti S, Rossi-Ferrini P. Inhibition of erythropoietin production in vitro by human interferon gamma. Br J Haematol 1994; 87: 18-23. [PMID: 7947242].
60. Balaiya S, Edwards J, Tillis T, Khetpal V, Chalam KV. Tumor necrosis factor-alpha (TNF-α) levels in aqueous humor of primary open angle glaucoma. Clin Ophthalmol. 2011; 5: 553-6. [PMID: 21607023].
61. Prata TS, Navajas EV, Melo LA Jr, Martins JR, Nader HB, Belfort R Jr. Aqueous humor protein concentration in patients with primary open-angle glaucoma under clinical treatment. Arq Bras Oftalmol 2007; 70: 217-20. [PMID: 17589689].
62. Grus FH, Joachim SC, Sandmann S, Thiel U, Bruns K, Lackner KJ, Pfeiffer N. Transthyretin and complex protein pattern in aqueous humor of patients with primary open-angle glaucoma. Mol Vis 2008; 14: 1437-45. [PMID: 18682810].
63. Inoue T, Kawaji T, Tanihara H. Elevated levels of multiple biomarkers of Alzheimer's disease in the aqueous humor of eyes with open-angle glaucoma. Invest Ophthalmol Vis Sci 2013; 54: 5353-8. [PMID: 23860758].
64. Silva-Araújo AC, Tavares MA, Cotta JS, Castro-Correia JF. Aqueous outflow system in familial amyloidotic polyneuropathy, Portuguese type. Graefes Arch Clin Exp Ophthalmol 1993; 231: 131-5. [PMID: 8385054].
65. Gherghel D, Hosking SL, Orgül S. Autonomic nervous system, circadian rhythms, and primary open-angle glaucoma. Surv Ophthalmol 2004; 49: 491-508. [PMID: 15325194].
66. Brown CM, Dütsch M, Michelson G, Neundörfer B, Hilz MJ. Impaired cardiovascular responses to baroreflex stimulation in open-angle and normal-pressure glaucoma. Clin Sci (Lond) 2002; 102: 623-30. [PMID: 12049615].
67. Clark CV, Mapstone R. Systemic autonomic neuropathy in open-angle glaucoma. Doc Ophthalmol 1986; 64: 179-85. [PMID: 3608758].
68. Kumar R, Ahuja VM. A study of changes in the status of autonomic nervous system in primary open angle glaucoma cases. Indian J Med Sci 1999; 53: 529-34. [PMID: 10862279].
69. Riccadonna M, Covi G, Pancera P, Presciuttini B, Babighian S, Perfetti S, Bonomi L, Lechi A. Autonomic system activity and 24-hour blood pressure variations in subjects with normal-and high-tension glaucoma. J Glaucoma 2003; 12: 156-63. [PMID: 12671471].
70. Küchle M, Nguyen NX, Hannappel E, Naumann GO. The blood-aqueous barrier in eyes with pseudoexfoliation syndrome. Ophthalmic Res 1995; 27: Suppl 1136-42. [PMID: 8577452].
71. Nguyen NX, Kuchle M, Naumann GO. Quantification of blood-aqueous barrier breakdown after phacoemulsification in Fuchs' heterochromic uveitis. Ophthalmologica 2005; 219: 21-5. [PMID: 15627823].